Stent Remains Available Despite Trial Displaying Dangers

A top critic says that the FDA has been remiss for not getting rid of a stent from the marketplace even though strong evidence exists that its use prospects to more deaths and strokes.

The Wingspan intracranial stent, produced by Stryker Neurovascular, was approved in 2005 by the FDA by means of the humanitarian device exemption (HDE) for the uncommon situation of intracranial atherosclerosis. The approval was based mostly on one single-arm review of 45 sufferers. But then in 2011 came the startling results of a considerably greater and well controlled trial from the NIH. 451 sufferers were randomized in the SAMMPRIS trial to both aggressive health-related treatment or the same medical treatment plus stenting with the Wingspan stent technique. The trial was terminated early due to a considerably higher price of stroke or death in the Wingspan group. In response to SAMMPRIS the FDA narrowed the indication for Wingspan but did not remove it from the marketplace.

Now, in a paper published in BMJ, a group of doctors led by Rita Redberg say that by not removing Wingspan from the marketplace the FDA is shirking its “responsibility to protect the public’s well being.”

The Wingspan saga demonstrates how large chance products can come to the market based on lower good quality clinical information. Moreover, the Wingspan device has not been removed from the market, even although a higher good quality randomized trial was prematurely terminated since of harms and no benefit. When gadgets are approved beneath the humanitarian exemption, restriction of their use to within randomized controlled trials could stop probably unsafe products from obtaining seemingly everlasting marketplace approval.

Though the FDA issued a safety communication in response to SAMMPRIS, Redberg and colleagues write that it is “vague in its terminology” and that the Wingspan web page on the Stryker site does not mention the more restricted indication. The authors cite data from Stryker displaying that the business shipped eleven,000 Wingspan products in the 6 many years following the first HDE approval study.

Stent Remains Available Despite Trial Displaying Dangers